ONCOLOGY: BREAST CANCER DIAGNOSTIC AND TREATMENT DEVICES | GLOBAL MARKETS

134 Pages | 32 Exhibits | 2018 Analysis | Forecasts Through 2022 Product Family: Market Reports




OVERVIEW:
This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for breast cancer diagnostic and treatment devices.

ONCOLOGY MARKET HIGHLIGHTS

  • Total Unit sales of diagnostic and treatment devices for breast cancer are increasing due to the increasing burden of breast cancer, accessibility to breast imaging and diagnostic technologies, and availability of new breast-conserving treatment options.
  • Diagnostic devices accounted for the majority of total sales of breast cancer diagnostic and treatment devices. Diagnostic devices for breast cancer accounted for approximately 98% of total product sales in 2017.
  • The global market for breast cancer diagnostic and treatment devices is anticipated to increase at a CAGR of 6.2% during the forecast period (2017-22), reaching approximately $5.96bn in total product sales by 2022.
  • The US was the largest market for diagnostic and treatment breast cancer device sales. Strong device sales in the US market are a result of favourable socioeconomic factors and a high participation rate by women in screening programs.
  • The competitive landscape is diverse due to the range of devices available for breast cancer diagnosis and treatment. Across diagnostic and therapeutic device markets covered, Hologic is the leading vendor based on Meddevicetracker estimates.
TOPICS COVERED INCLUDE:
  • An overview of diagnostic and therapeutic devices used in the management of breast cancer patients.
  • Diagnostic products covered by this report include mammorgraphy and other imaging systems, CAD software for diagnostic breast cancer imaging, and biopsy devices.
  • Breast cancer treatment devices covered by this report include lumpectomy guidance systems, breast irradiation systems, and minimally invasive ablation devices.
  • Global and country/region-specific market forecasts, including forecasts by product segment.
  • Competitive analyses.
  • Discussion of key drivers and limiters impacting the market for diagnostic and treatment devices for breast cancer.
  • A review of emerging technologies which could impact sales of existing devices.


TABLE OF CONTENTS:
Executive Summary 

i. Breast cancer overview 
ii. Global breast cancer market 
	a. Market drivers and limiters 
	b. Breast cancer imaging, biopsy, and tissue-sparing treatments overview 
	c. Technology trends 
	d. Market leaders 
	e. Competitive strategies 
	f. Emerging competition 
iii Methodology 

Exhibit ES-1: Breast imaging and biopsy products, global market forecast ($m), 2017-22 
Exhibit ES-2: Partial breast irradiation and ablation treatments for breast cancer, global market forecast ($m), 2017-22 

1. Breast Cancer Overview
 
1.1 Risk factors 
1.2 Detection and diagnosis 
	1.2.1 Clinical breast exam 
	1.2.2 Screening mammography 
		1.2.2.1 Limitations of screening mammography 
		1.2.2.2 National screening programs 
		1.2.2.3 Overdiagnosis controversies 
		1.2.2.4 Personalized breast screening 
		1.2.2.5 Types of mammography system 
		1.2.2.6 Installed base of mammography systems 
	1.2.3 Other breast cancer imaging technologies 
		1.2.3.1 Breast MRI 
		1.2.3.2 Automated breast ultrasound 
		1.2.3.3 Molecular breast imaging 
		1.2.3.4 Positron emission mammography 
		1.2.3.5 Tomographic optical breast imaging 
		1.2.3.6 Radiofrequency imaging 
	1.2.4 Biopsy 
	1.2.5 Sample testing 
		1.2.5.1 Gene expression profiling 
		1.2.5.2 Protein expression profiling (IHC) 
1.3 Treatment pathways 
	1.3.1 Surgery 
	1.3.2 Ablative therapies 
	1.3.3 Chemotherapy 
	1.3.4 Radiation therapy 
	1.3.5 Hormone therapy
	1.3.6 Targeted treatments 
1.4 Bibliography 

Exhibit 1-1: Estimated incident cases of breast cancer by molecular subtype, US, 2017 and 2022
Exhibit 1-2: Estimated incident cases of breast cancer by molecular subtype, 5EU, 2017 and 2022 
Exhibit 1-3: Estimated incident cases of breast cancer by molecular subtype, Japan, 2017 and 2022 
Exhibit 1-4: Estimated incident cases of breast cancer by stage, US, 2017 and 2022 
Exhibit 1-5: Estimated incident cases of breast cancer by stage, 5EU, 2017 and 2022 
Exhibit 1-6: Estimated incident cases of breast cancer by stage, Japan, 2017 and 2022 
Exhibit 1-7: Factors that increase the relative risk for breast cancer in women 
Exhibit 1-8: National screening guidelines for breast cancer and possible changes (in bold) 
Exhibit 1-9: Developments in breast screening technology 
Exhibit 1-10: Installed base of mammography systems in the US, Japan, and 5EU 

2. Breast Cancer Imaging and Biopsy Products
 
2.1 Mammography and other imaging products 
	2.1.1 Film-based mammography systems 
	2.1.2 Computed radiography systems 
	2.1.3 FFDM systems 
	2.1.4 Digital breast tomosynthesis systems 
		2.1.4.1 Fujifilm 
		2.1.4.2 GE Healthcare 
		2.1.4.3 General Medical Merate 
		2.1.4.4 Hologic 
		2.1.4.5 Planmed Oy 
		2.1.4.6 Siemens Healthineers 
	2.1.5 CAD software 
		2.1.5.1 Selected commercial CAD systems 
		2.1.5.2 Future developments 
	2.1.6 Automated breast ultrasound systems
	2.1.7 Breast-specific MRI coils 
	2.1.8 Computed tomography 
2.2 Stereotactic biopsy guidance systems 
2.3 Minimally invasive biopsy products 
	2.3.1 Core-needle biopsy systems 
	2.3.2 VAB systems 
2.4 Breast cancer imaging and biopsy products market 
	2.4.1 Global market insights 
	2.4.2 Market value 
	2.4.3 Segment insights 
		2.4.3.1 Mammography 
		2.4.3.2 ABUS 
		2.4.3.3 MRI coils 
		2.4.3.4 Biopsy systems 
	2.4.4 Regional insights 
		2.4.4.1 Market forecast: US 
		2.4.4.2 Market forecast: Five major EU markets 
		2.4.4.3 Market forecast: Japan 
		2.4.4.4 Market forecast: Rest of the world 
	2.4.5 Market trends 
	2.4.6 Market drivers and limiters 
	2.4.7 Market leaders 
		2.4.7.1 Hologic 
		2.4.7.2 GE Healthcare 
		2.4.7.3 Siemens Healthineers 
		2.4.7.4 Other major players 
2.5 Bibliography 

Exhibit 2-1: Selected FFDM systems 
Exhibit 2-2: Selected ongoing trials comparing synthetic mammography/DBT to FFDM 
Exhibit 2-3: Selected digital breast tomography (DBT) systems 
Exhibit 2-4: Selected commercially available ABUS systems 
Exhibit 2-5: Selected stereotactic biopsy guidance systems and tables 
Exhibit 2-6: Breast imaging and biopsy products, combined market forecast, by product segment ($m), 2017-22 
Exhibit 2-7: Mammography systems, combined market forecast, by product segment ($m), 2017-22 
Exhibit 2-8: ABUS systems, global market forecast ($m), 2017-22 
Exhibit 2-9: Global MRI coil sales, market forecast ($m), 2017-22 
Exhibit 2-10: Biopsy systems, global market forecast ($m), 2017-22 
Exhibit 2-11: Breast imaging and biopsy products, US market forecast ($m), 2017-22 
Exhibit 2-12: Breast imaging and biopsy products, 5EU market forecast ($m), 2017-22 
Exhibit 2-13: Breast imaging and biopsy products, Japan market forecast ($m), 2017-22 
Exhibit 2-14: Breast imaging and biopsy products, RoW market forecast ($m), 2017-22 
Exhibit 2-15: Breast imaging and biopsy systems market, share by supplier, 2017 

3. Breast Cancer Treatment Devices
 
3.1 Breast cancer surgery 
	3.1.1 Lumpectomy guidance systems 
3.2 Breast irradiation 
	3.2.1 EBRT 
	3.2.2 Accelerated partial breast irradiation 
		3.2.2.1 EBRT for APBI 
		3.2.2.2 High-dose rate brachytherapy 
		3.2.2.3 Image-guided radiation therapy 
		3.2.2.4 IORT 
		3.2.2.5 Stereotactic radiotherapy 
		3.2.2.6 Current recommendations for the use of APBI 
	3.2.3 3D tissue marker for breast irradiation 
3.3 Minimally invasive ablation of breast cancer 
	3.3.1 Cryoablation 
		3.3.1.1 Products under development 
	3.3.2 Laser interstitial thermotherapy 
3.4 Partial breast irradiation and ablation treatments products market 
	3.4.1 Market value 
	3.4.2 Partial breast irradiation and ablation systems - segment insights 
	3.4.3 Regional insights 
	3.4.4 Trends in the partial breast irradiation and ablation systems market 
		3.4.4.1 Mergers and acquisitions 
		3.4.4.2 Reimbursement trends 
		3.4.4.3 Treatment trends 
		3.4.4.4 Technology trends 
	3.4.5 Market drivers and limiters 
	3.4.6 Market leaders 
3.5 Bibliography 

Exhibit 3-1: Lumpectomy, procedure volumes forecast, selected countries/regions, 2017-22 
Exhibit 3-2: Selected APBI systems 
Exhibit 3-3: Partial breast irradiation and ablation product sales, combined market forecast, by product segment ($m), 2017-22 
Exhibit 3-4: Global partial breast irradiation and ablation systems sales and share by country/region, 2017 
Exhibit 3-5: APBI systems market, share by supplier, 2017 

Appendix: Company Listing


COMPANIES COVERED:

  1. AccuBoost
  2. Accuray
  3. Adani Systems
  4. Allengers Medical Systems
  5. Amico JSC
  6. Angell Technology
  7. Anke
  8. Ariane Medical Systems
  9. Argon Medical Devices
  10. BD
  11. Biomedical International
  12. Canon
  13. Cardinal Health
  14. Carestream Health/Onex Corporation
  15. Carl Zeiss
  16. Cianna Medical
  17. Cook Medical/Cook Group
  18. C.R. Bard/BD
  19. Delphinus Medical Technologies
  20. Densitas
  21. Devicor Medical Products/Leica Biosystems/Danaher
  22. Dune Medical
  23. EcoRay
  24. Elekta
  25. Focal Therapeutics
  26. Fujifilm
  27. Galen MRI Systems
  28. Gallini Medical Devices
  29. GE Healthcare
  30. General Medical merate S.p.A
  31. Genentech/Roche
  32. Google
  33. Hitachi
  34. Hologic
  35. iCad
  36. IceCure Medical
  37. INRAD
  38. IntraOp Medical
  39. Invivo/Philips Healthcare
  40. Italray
  41. Konica Minolta
  42. Koning Corporation
  43. Metaltronica
  44. Micrima
  45. NeoGenomics Laboratories
  46. Novartis
  47. Novian Health
  48. Parascript
  49. Philips Healthcare
  50. Planmed Oy
  51. Sanarus Technologies
  52. ScreenPoint Medical
  53. Siemens Healthineers
  54. SonoCine
  55. Sordina IORT Technologies S.p.A.
  56. TSK Laboratory
  57. Varian Medical Systems
  58. Volpara Solutions
  59. Xcision Medical Systems
Contact Us

Need help finding medtech research? Let us help you!